Evaxion A/S Files 6-K Report

Ticker: EVAX · Form: 6-K · Filed: 2025-08-14T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 6-K, reporting

TL;DR

Evaxion A/S filed its Q2 2025 6-K, check exhibits 99.1 & 99.2 for updates.

AI Summary

Evaxion Biotech A/S, now Evaxion A/S, filed a Form 6-K on August 14, 2025, reporting for the period ending June 30, 2025. The filing includes exhibits 99.1 and 99.2, which are incorporated by reference. The company is a foreign private issuer based in Hoersholm, Denmark.

Why It Matters

This filing provides an update on the company's reporting status and includes key exhibits for investors to review regarding its financial and operational status as of Q2 2025.

Risk Assessment

Risk Level: low — This is a routine periodic filing (6-K) and does not appear to contain new material events or significant financial changes.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report information that Evaxion A/S is required to disclose to its security holders or the public under Danish law or its articles of incorporation, and to provide updates for the period ending June 30, 2025.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed with the SEC on August 14, 2025.

What is the reporting period covered by this filing?

This filing reports for the period ending June 30, 2025 (Q2 2025).

What exhibits are incorporated by reference in this filing?

Exhibits 99.1 and 99.2 of this report on Form 6-K are incorporated by reference.

What was Evaxion A/S's former company name?

Evaxion A/S's former company name was Evaxion Biotech A/S, with a date of name change on October 14, 2020.

From the Filing

0001171843-25-005404.txt : 20250814 0001171843-25-005404.hdr.sgml : 20250814 20250814073017 ACCESSION NUMBER: 0001171843-25-005404 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250814 DATE AS OF CHANGE: 20250814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251214347 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 evax20250806_6k.htm FORM 6-K evax20250814_6k.htm 0001828253 June 30, 2025 false --12-31 Q2 2025   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 6-K     REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of August 2025   Commission File Number: 001-39950     Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter)     Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F ☒               Form 40-F ☐         INCORPORATION BY REFERENCE   Exhibits 99.1 and 99.2 of this report on Form 6 -K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S- 8 (File No. 333 - 255064 ), on Form F- 3 (File No. 333 - 265132 ) and on Form F- 1 (File No. 333 - 266050 ), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.   Furnished as Exhibits to this Report on Form 6 -K is information regarding the Company’s financial results for the fiscal quarter ended June 30, 2025.                 Exhibits   Exhibit     No.   Description 99.1   Unaudited Condensed Consolidated Interim Financial Statements. 99.2   Management’s Discussion and Analysis of Financial Condition and Results of Operations. 101.INS   Inline XBRL Instance Document 101.SCH   Inline XBRL Taxonomy Extension Schema 101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase 101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase 101.LAB   Inline XBRL Taxonomy Extension Label Linkbase 101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase 104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)                     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     Evaxion Biotech A/S       Date: August 13, 2025 By: /s/ Birgitte Rønø     Birgitte Rønø     Chief Executive Officer               Date: August 13, 2025 By: /s/ Thomas Frederik Schmidt     Thomas Frederik Schmidt     Chief Financi

View on Read The Filing